Caspofungin for post solid organ transplant invasive fungal disease: Results of a retrospective observational study

Transplant Infectious Disease

Volumn 12, Issue 3, 2010, Pages 230-237

  Winkler, M ^a   Pratschke, J ^b   Schulz, U ^c   Zheng, S ^d   Zhang, M ^d   Li, W ^e   Lu, M ^f   Sgarabotto, D ^g   Sganga, G ^h   Kaskel, P ⁱ   Chandwani, S ^j   Ma, L ^k   Petrovic, J ^l   Shivaprakash, M ^k  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d ZHEJIANG UNIVERSITY   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f SUN YAT SEN UNIVERSITY   (China)

^g UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ MSD Sharp and Dohme GmbH   (Germany)

^j UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^k MERCK RESEARCH LABORATORIES   (United States)

^l Merck Research Laboratories   (Italy)

more..

Author keywords

Aspergillosis; Candidiasis; Caspofungin; Invasive fungal disease; Solid organ transplant

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; BASILIXIMAB; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; FLUCONAZOLE; ITRACONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDIASIS; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; NAUSEA; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PATIENT SAFETY; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SURVIVAL RATE; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; CHINA; CLINICAL TRIAL; GERMANY; ITALY; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RETROSPECTIVE STUDY; UNITED KINGDOM; YOUNG ADULT;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHINA; ECHINOCANDINS; FEMALE; GERMANY; GREAT BRITAIN; HUMANS; ITALY; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953193159     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2009.00490.x     Document Type: Article

References (30)

1. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996 62 (7) : 926 934.
2. Solé A, Salavert M. Fungal infections after lung transplantation. Transplant Rev (Orlando) 2008 22 (2) : 89 104.
3. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003 37 (2) : 221 229.
4. Miller LW, Naftel DC, Bourge RC, et al. Infection after heart-transplantation - a multiinstitutional study. J Heart Lung Transplant 1994 13 (3) : 381 393.
5. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001 3 (3) : 128 137.
6. Gabardi. S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int 2007 20 (12) : 993 1015.
7. Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 2007 26 (12) : 879 886.
8. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999 78 (2) : 123 138.
9. Pugliese F, Ruberto F, Cappannoli A, et al. Incidence of fungal infections in a solid organ recipients dedicated intensive care unit. Transplant Proc 2007 39 (6) : 2005 2007.
10. Gavalda J, Len O, San Juan R, et al RESITRA (Spanish Network for Research in Infection in Transplantation). Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005 41 (1) : 52 59.
11. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007 45 (4) : 305 320.
12. Petrovic J, Ngai A, Bradshaw S, et al. Efficacy and safety of caspofungin in solid organ transplant recipients. Transplant Proc 2007 39 (10) : 3117 3120.
13. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National institute of allergy and infectious diseases mycoses study group. N Engl J Med 1999 340 (10) : 764 771.
14. Herbrecht R. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 (6) : 408 415. (Pubitemid 34851833)
15. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 351 (14) : 1391 1402.
16. Muñoz P, Rodríguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 2004 4 (4) : 636 643.
17. Anttila VJ, Piilonen A, Valtonen M. Co-administration of caspofungin and cyclosporine to a kidney transplant patient with pulmonary Aspergillus infection. Scand J Infect Dis 2003 35 (11-12) : 893 894.
18. Saner F, Gensicke J, Rath P, et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006 34 (6) : 328 332.
19. Veroux M, Corona D, Macarone M, Gagliano M, Giuffida G, Veroux P. Caspofungin in kidney transplant recipients with refractory invasive candidiasis. Nephrol Dial Transplant 2007 22 (5) : 1487 1489.
20. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 (1) : 7 14.
21. Kremers WK, van IJperen M, Kim WR, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004 39 (3) : 764 769.
22. Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005 41 (3) : 301 307.
23. Ullmann AJ, Sanz MA, Tramarin A, et al. Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006 43 (4) : 29 38.
24. Said T, Nampoory MR, Nair MP, et al. Safety of caspofungin for treating invasive nasal sinus aspergillosis in a kidney transplant recipient. Transplant Proc 2005 37 (7) : 3038 3040.
25. Forestier E, Remy V, Lesens O, et al. A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole. Eur J Clin Microbiol Infect Dis 2005 24 (5 347 349.
26. Eschertzhuber S, Velik-Salchner C, Hoermann C, Hoefer D, Lass-Florl C. Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report. Transpl Infect Dis 2008 10 (3) : 190 192.
27. Veroux M, Corona D, Gagliano M, et al. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients. Transplant Proc 2007 39 (6) : 1838 1840. (Pubitemid 47198782)
28. Fujishita M, Kataoka R, Kobayashi M, Miyoshi I. [Clinical features of 32 cases of fungal pneumonia]. Nihon Kyobu Shikkan Gakkai Zasshi 1991 29 (4) : 420 428.
29. Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 2008 27 (1) : 1 6.
30. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003 75 (12) : 2023 2029.